ATE494893T1 - Sulfonamide, sulfamate und sulfamide als gamma- secretase-hemmer - Google Patents
Sulfonamide, sulfamate und sulfamide als gamma- secretase-hemmerInfo
- Publication number
- ATE494893T1 ATE494893T1 AT03809792T AT03809792T ATE494893T1 AT E494893 T1 ATE494893 T1 AT E494893T1 AT 03809792 T AT03809792 T AT 03809792T AT 03809792 T AT03809792 T AT 03809792T AT E494893 T1 ATE494893 T1 AT E494893T1
- Authority
- AT
- Austria
- Prior art keywords
- sulfamates
- sulfamides
- sulfonamides
- gamma secretase
- secretase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0225474.6A GB0225474D0 (en) | 2002-11-01 | 2002-11-01 | Therapeutic agents |
| PCT/GB2003/004707 WO2004039370A1 (en) | 2002-11-01 | 2003-10-29 | Sulfonamides, sulfamates and sulfamides as gamma-secretase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE494893T1 true ATE494893T1 (de) | 2011-01-15 |
Family
ID=9947009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03809792T ATE494893T1 (de) | 2002-11-01 | 2003-10-29 | Sulfonamide, sulfamate und sulfamide als gamma- secretase-hemmer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7144910B2 (de) |
| EP (1) | EP1560580B1 (de) |
| JP (1) | JP4536517B2 (de) |
| AT (1) | ATE494893T1 (de) |
| AU (1) | AU2003276435B2 (de) |
| CA (1) | CA2503868C (de) |
| DE (1) | DE60335731D1 (de) |
| GB (1) | GB0225474D0 (de) |
| WO (1) | WO2004039370A1 (de) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7365196B2 (en) * | 2000-03-20 | 2008-04-29 | Merck Sharp & Dohme Ltd. | Sulphonamido-substituted bridged bicycloalkyl derivatives |
| RU2304140C2 (ru) | 2001-12-27 | 2007-08-10 | Дайити Фармасьютикал Ко., Лтд. | ИНГИБИТОРЫ ПРОДУЦИРОВАНИЯ / СЕКРЕЦИИ β-АМИЛОИДНОГО БЕЛКА |
| GB0308318D0 (en) * | 2003-04-10 | 2003-05-14 | Merck Sharp & Dohme | Therapeutic agents |
| RU2336270C2 (ru) | 2003-06-30 | 2008-10-20 | Дайити Фармасьютикал Ко., Лтд. | Гетероциклические метилсульфоновые производные |
| CA2539042A1 (en) * | 2003-09-24 | 2005-04-07 | Merck Sharp & Dohme Limited | Gamma-secretase inhibitors |
| EP1888050B1 (de) | 2005-05-17 | 2012-03-21 | Merck Sharp & Dohme Ltd. | Cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropansäure zur Behandlug von Krebs |
| US20080058316A1 (en) | 2006-02-27 | 2008-03-06 | The Johns Hopkins University | Cancer treatment with gama-secretase inhibitors |
| JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
| EP2094836B1 (de) | 2006-11-15 | 2016-06-08 | Massachusetts Eye & Ear Infirmary | Erzeugung von innerohrzellen |
| EP2091948B1 (de) | 2006-11-30 | 2012-04-18 | Probiodrug AG | Neue inhibitoren von glutaminylcyclase |
| AU2008215948A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of AD and related conditions |
| CA2679446C (en) | 2007-03-01 | 2016-05-17 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
| US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| US8377886B2 (en) * | 2007-09-14 | 2013-02-19 | Albert Einstein College Of Medicine Of Yeshiva University | Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease |
| US8461389B2 (en) | 2008-04-18 | 2013-06-11 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
| HUE043090T2 (hu) * | 2008-06-09 | 2019-08-28 | Univ Muenchen Ludwig Maximilians | Gyógyszerek fehérjék aggregálódásának gátlására olyan betegségeknél, amelyek fehérje-aggregálódással és/vagy neurodegeneratív megbetegedésekkel függnek össze |
| CA2743436C (en) | 2008-11-24 | 2017-10-31 | Massachusetts Eye & Ear Infirmary | Pathways to generate hair cells |
| US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| BR112012008346B1 (pt) | 2009-09-11 | 2021-12-21 | Vivoryon Therapeutics N.V. | Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica |
| EP2488028B1 (de) | 2009-10-14 | 2020-08-19 | Merck Sharp & Dohme Corp. | Substituierte piperidine zur erhöhung der p53-aktivität und ihre verwendung |
| EP2488031A4 (de) * | 2009-10-16 | 2014-07-23 | Merck Sharp & Dohme | Diaryletherderivate als notch-umgehende gammasekretasehemmer |
| WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
| DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
| EP2560953B1 (de) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Hemmer der glutaminylzyklase |
| WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| CN107090456B (zh) | 2010-08-02 | 2022-01-18 | 瑟纳治疗公司 | 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制 |
| JP2013537423A (ja) | 2010-08-17 | 2013-10-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| EP2615916B1 (de) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Kondensierte pyrazolderivate als neue erk-hemmer |
| DK2632472T3 (en) | 2010-10-29 | 2018-03-19 | Sirna Therapeutics Inc | RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA) |
| WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
| WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| EP2844261B1 (de) | 2012-05-02 | 2018-10-17 | Sirna Therapeutics, Inc. | Sina-zusammensetzungen |
| HK1211875A1 (en) | 2012-09-07 | 2016-06-03 | Massachusetts Eye & Ear Infirmary | Treating hearing loss |
| JP6486272B2 (ja) | 2012-09-07 | 2019-03-20 | マサチューセッツ・アイ・アンド・イア・インファーマリー | 有毛細胞および／または支持細胞再生のための方法および組成物 |
| CN105050598B (zh) | 2012-09-28 | 2018-04-27 | 默沙东公司 | 作为erk抑制剂的新型化合物 |
| RS56680B1 (sr) | 2012-11-28 | 2018-03-30 | Merck Sharp & Dohme | Kompozicije i postupci za lečenje kancera |
| US8846657B2 (en) | 2012-12-20 | 2014-09-30 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as HDM2 inhibitors |
| WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| US8859286B2 (en) | 2013-03-14 | 2014-10-14 | Viacyte, Inc. | In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells |
| EP3041938A1 (de) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Kreisförmige polynukleotide |
| BR112017000130A2 (pt) | 2014-07-11 | 2018-01-09 | Genentech Inc | método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer |
| WO2016022776A2 (en) | 2014-08-06 | 2016-02-11 | Massachusetts Eye And Ear Infirmary | Increasing atoh1 life to drive sensorineural hair cell differentiantion |
| SG10201913841SA (en) | 2015-07-24 | 2020-03-30 | Oncotracker Inc | Gamma secretase modulators for the treatment of immune system dysfunction |
| US11185536B2 (en) | 2015-12-04 | 2021-11-30 | Massachusetts Eye And Ear Infirmary | Treatment of hearing loss by inhibition of casein kinase 1 |
| CN109219439B (zh) | 2016-01-29 | 2022-09-20 | 马萨诸塞眼科耳科诊所 | 内耳支持细胞的扩增和分化及其使用方法 |
| CA3024424A1 (en) | 2016-05-16 | 2017-11-23 | The General Hospital Corporation | Human airway stem cells in lung epithelial engineering |
| US10975084B2 (en) | 2016-10-12 | 2021-04-13 | Merck Sharp & Dohme Corp. | KDM5 inhibitors |
| JP6904612B2 (ja) | 2016-12-16 | 2021-07-21 | パイプライン セラピューティクス， インコーポレイテッド | 蝸牛シナプス障害を処置する方法 |
| CN110461335A (zh) | 2017-02-17 | 2019-11-15 | 弗雷德哈钦森癌症研究中心 | 用于治疗bcma相关癌症和自身免疫性失调的联合疗法 |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| EP3706742B1 (de) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| US11098059B2 (en) | 2017-11-08 | 2021-08-24 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| EP3833668B1 (de) | 2018-08-07 | 2025-03-19 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| WO2020033285A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| CA3108388A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3833667B1 (de) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| WO2021126728A1 (en) | 2019-12-17 | 2021-06-24 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| JP7589247B2 (ja) | 2019-12-17 | 2024-11-25 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｐｒｍｔ５阻害剤 |
| EP4076460B1 (de) | 2019-12-17 | 2026-01-21 | Merck Sharp & Dohme LLC | 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidin]-derivate als prmt5 inhibitoren zur behandlung von krebs |
| WO2021195362A1 (en) | 2020-03-26 | 2021-09-30 | Seagen Inc. | Methods of treating multiple myeloma |
| GEAP202516720A (en) | 2022-09-02 | 2025-07-10 | Merck Sharp & Dohme Llc | Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof |
| IL320396A (en) | 2022-10-25 | 2025-06-01 | Merck Sharp & Dohme Llc | Charge-linkers of anti-drug conjugates derived from extacan, pharmaceutical compositions, and uses thereof |
| US20240207425A1 (en) | 2022-12-14 | 2024-06-27 | Merck Sharp & Dohme Llc | Auristatin linker-payloads, pharmaceutical compositions, and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7365196B2 (en) * | 2000-03-20 | 2008-04-29 | Merck Sharp & Dohme Ltd. | Sulphonamido-substituted bridged bicycloalkyl derivatives |
| DE60112957T2 (de) * | 2000-11-02 | 2006-05-18 | Merck Sharp & Dohme Ltd., Hoddesdon | Sulfamide als gamma-secretase-inhibitoren |
-
2002
- 2002-11-01 GB GBGB0225474.6A patent/GB0225474D0/en not_active Ceased
-
2003
- 2003-10-29 AT AT03809792T patent/ATE494893T1/de not_active IP Right Cessation
- 2003-10-29 JP JP2004547808A patent/JP4536517B2/ja not_active Expired - Fee Related
- 2003-10-29 US US10/533,151 patent/US7144910B2/en not_active Expired - Fee Related
- 2003-10-29 CA CA2503868A patent/CA2503868C/en not_active Expired - Fee Related
- 2003-10-29 EP EP03809792A patent/EP1560580B1/de not_active Expired - Lifetime
- 2003-10-29 WO PCT/GB2003/004707 patent/WO2004039370A1/en not_active Ceased
- 2003-10-29 AU AU2003276435A patent/AU2003276435B2/en not_active Ceased
- 2003-10-29 DE DE60335731T patent/DE60335731D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1560580B1 (de) | 2011-01-12 |
| US20060069147A1 (en) | 2006-03-30 |
| WO2004039370A1 (en) | 2004-05-13 |
| JP2006506390A (ja) | 2006-02-23 |
| DE60335731D1 (de) | 2011-02-24 |
| JP4536517B2 (ja) | 2010-09-01 |
| AU2003276435A1 (en) | 2004-05-25 |
| EP1560580A1 (de) | 2005-08-10 |
| AU2003276435B2 (en) | 2008-10-16 |
| CA2503868A1 (en) | 2004-05-13 |
| CA2503868C (en) | 2011-09-20 |
| GB0225474D0 (en) | 2002-12-11 |
| US7144910B2 (en) | 2006-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE494893T1 (de) | Sulfonamide, sulfamate und sulfamide als gamma- secretase-hemmer | |
| ATE464287T1 (de) | Cyclohexyl-sulphone als gamma-sekretase- inhibitoren | |
| DE60112957D1 (de) | Sulfamide als gamma-secretase-inhibitoren | |
| ATE444293T1 (de) | Cyclische sulfamide zur inhibierung von gamma- sekretase | |
| ATE368031T1 (de) | Neue gamma secretase inhibitoren | |
| MXPA05012323A (es) | Sulfonamidas ciclicas para la inhibicion de gama-secretasa. | |
| DE60328182D1 (de) | Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase | |
| DE60144064D1 (de) | Sulfone, die die aktivität von gamma-secretase modulieren | |
| ATE354563T1 (de) | Sulfonderivate zur hemmung von gamma-secretase | |
| NO20005237D0 (no) | Heterocyklisk substituerte amider anvendt som calpain- inhibitorer | |
| TNSN02012A1 (fr) | Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant | |
| DE60237725D1 (de) | Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit | |
| DE60134874D1 (de) | Benzodiazepin-derivate als gamma-secretase inhibitoren | |
| ATE353217T1 (de) | 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren | |
| ATE524452T1 (de) | Sulfonamide zur behandlung von kongestivem herzversagen, deren zusammensetzungen und verwendungen. | |
| ES2282685T3 (es) | Derivados de hidroxietilamina para el tratamiento de la enfermedad de alzheimer. | |
| ATE354562T1 (de) | Cyclohexylsulfon-derivate als gamma-secretase- inhibitoren | |
| PE20071321A1 (es) | Bencensulfonil-cromano, tiocromano, tetrahidronaftaleno e inhibidores de gamma secretasa relacionados | |
| EA200700035A1 (ru) | Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных di sorders | |
| ATE446285T1 (de) | Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3- thiosubstituierte indol-2-alkinsäuren | |
| DK1463735T3 (da) | Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider | |
| DOP2002000451A (es) | Nuevas ciclohexilsulfonas (agentes terapéuticos) | |
| BR9813719A (pt) | Agentes terapêuticos | |
| DE602004026597D1 (de) | Behandlung von alzheimer-krankheit und verwandten zuständen | |
| ATE373637T1 (de) | N-(2-phenylethyl)sulfamid-derivate als integrin- alpha4-antagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |